IP Library Patent Application 17798491
Patent Application
App. No. 17/798,491

COMPOSITIONS COMPRISING METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/798,491
Abstract

The present technology is directed serdexmethylphenidate compounds and methods for synthesizing a compound having the formula

Claims (46)

1 . A method for manufacture of a serdexmethylphenidate chloride compound having formula I:

the method comprising:

(a) synthesizing a compound having formula II:

(b) synthesizing a first intermediate compound having formula III:

(c) synthesizing a second intermediate compound having formula IV:

(d) synthesizing a crude product of the serdexmethylphenidate chloride compound,

(e) purifying the compound having formula V to produce the serdexmethylphenidate chloride compound having formula I.

2 . The method of claim 1 , further comprising:

(f) determining the purity level of the serdexmethylphenidate chloride compound having formula I.

3 . The method of claim 1 , wherein if impurities are detected, the serdexmethylphenidate chloride compound undergoes an additional purification step comprising:

(a) reacting the serdexmethylphenidate chloride crystalline solid with isopropyl alcohol to produce a reaction mixture; and

(b) adding serdexmethylphenidate chloride seed crystals to the reaction mixture to yield the serdexmethylphenidate chloride compound having formula I as a crystalline solid.

4 . The method of claim 1 , wherein synthesis of the compound having formula II comprises reacting O-tert-butyl-L-serine tert-butyl ester hydrochloride and nicotinic acid in the presence of triethylamine in methyl-t-butyl ether and acetonitrile.

5 . The method of claim 4 , wherein following the reaction of O-tert-butyl-L-serine tert-butyl ester hydrochloride and nicotinic acid in the presence of triethylamine in methyl-t-butyl ether and acetonitrile, the resulting solution is crystallized suing methyl-t-butyl ether and n-heptane to yield the compound having formula II.

6 . The method of claim 1 , wherein synthesis of the first intermediate compound comprises:

(a) reacting dexmethylphenidate HCl with methyl-t-butyl ether and 2,6-lutidine to obtain a reaction mixture; and

(b) adding chloromethyl chloroformate to the reaction mixture to yield the first intermediate compound.

7 . The method of claim 1 , wherein synthesis of the second intermediate compound comprises:

(a) reacting the compound having formula II with the first intermediate compound in the presence of acetonitrile, HCl in dioxane, and 4-methyl-2-pentanone to obtain a reaction mixture; and

(b) adding serdexmethylphenidate chloride seed crystals to the reaction mixture to yield the second intermediate compound as a crystalline solid.

8 . The method of claim 1 , wherein synthesis of the crude product of the serdexmethylphenidate chloride compound having formula V comprises:

(a) reacting the second intermediate crystalline solid with anyhydrous 1,4 dioxane and sulfolane to produce a reaction mixture; and

(b) adding serdexmethylphenidate chloride seed crystals to the reaction mixture to yield the crude product of the serdexmethylphenidate chloride compound having formula V.

9 . The method of claim 1 , wherein purifying the crude product of the serdexmethylphenidate chloride compound comprises:

(a) reacting the crude product with acetone to produce a reaction mixture; and

(b) adding serdexmethylphenidate chloride seed crystals to the reaction mixture to yield the serdexmethylphenidate chloride compound having formula I as a crystalline solid.

10 . A method of manufacture of a serdexmethylphenidate chloride and dexmethylphenidate hydrochloride capsule comprising:

(a) blending a quantity of serdexmethylphenidate chloride compound having formula I:

and a quantity of dexmethylphenidate hydrochloride;

(b) adding a first quantity of microcrystalline cellulose to the blender and mixing to produce a pre-blend;

(c) adding a second quantity of microcrystalline cellulose and a quantify of crospovidone to the pre-blend to produce an intra-granular primary blend;

(d) mixing the intra-granular primary blend;

(e) adding a first quantity of magnesium stearate to the intra-granular primary blend to produce an intra-granular lubrication blend;

(e) mixing the intra-granular lubrication blend;

(f) granulating the intra-granular lubrication blend using a roller compactor;

(g) milling the intra-granular lubrication blend;

(h) adding a quantity of colloidal silicon dioxide and talc to the milled intra-granular lubrication blend to produce an extra-granular primary blend;

(i) mixing the extra-granular primary blend with a second quantity of magnesium stearate to produce an extra-granular lubrication blend;

(j) mixing the extra-granular lubrication blend; and

(k) encapsulating the extra-granular lubrication blend in a capsule.

11 . The method of claim 10 , wherein the capsule is a size 3 HPMC capsule.

12 . The method of claim 10 , wherein the pre-blend is mixed for 130 revolutions.

13 . The method of claim 10 , wherein the intra-granular primary blend is mixed for 260 revolutions.

14 . The method of claim 10 , wherein the intra-granular lubrication blend is mixed for 130 revolutions.

15 . The method of claim 10 , wherein the extra-granular primary blend is mixed for 260 revolutions.

16 . The method of claim 10 , wherein the extra-granular lubrication blend is mixed for 130 revolutions.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2026
From: ZEVRA THERAPEUTICS, INC.
To: COMMAVE THERAPEUTICS SA
Reel/Frame 074195/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2026
From: ZEVRA THERAPEUTICS, INC.
To: COMMAVE THERAPEUTICS SA
Reel/Frame 074186/0531 →
RELEASE OF SECURITY INTEREST Recorded Mar 13, 2026
From: ALTER DOMUS (US) LLC
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 075080/0907 →
SECURITY INTEREST Recorded Apr 8, 2024
From: ZEVRA THERAPEUTICS, INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 067040/0637 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2023
From: GUENTHER, SVEN; CHI, GUOCHEN; MICKLE, TRAVIS
To: KEMPHARM, INC.
Reel/Frame 064387/0764 →
CHANGE OF NAME Recorded Jul 26, 2023
From: KEMPHARM, INC.
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 064388/0285 →